Sangamo BioSciences | SGMO - Assets


Sangamo BioSciences reported $97.56M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 92.5B 1.92B Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 145.86M 10.71M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Grifols EUR 23.15B 142.7M Dec/2025
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 207.62B 542M Mar/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026